Arcus Biosciences Inc
NYSE:RCUS
Arcus Biosciences Inc
Change in Working Capital
Arcus Biosciences Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arcus Biosciences Inc
NYSE:RCUS
|
Change in Working Capital
$22m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
194%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Change in Working Capital
-$2.8B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Change in Working Capital
-$880m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Change in Working Capital
$2.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
8%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Change in Working Capital
-$514.8m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-22%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Change in Working Capital
-$618.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
Arcus Biosciences Inc
Glance View
Arcus Biosciences Inc., founded in 2015 and based in California, emerges not just as a company, but as a dynamic player in the biopharmaceutical arena with a fervent focus on innovative cancer therapies. The company's narrative is centered around harnessing the power of immunotherapy to combat cancer, a testament to its commitment to push the frontiers of medicine. At the core of Arcus's strategy is its proprietary pipeline of novel molecules designed to promote antitumor immune responses, particularly small-molecule drugs and antibodies. By marrying cutting-edge science with practical clinical applications, Arcus aims to provide treatments that enhance the body's immune response against cancer, offering hope to patients and healthcare providers alike. As Arcus Biosciences spins its operational wheel, its financial engine is fueled primarily through strategic partnerships and licensing agreements. The company collaborates with major pharmaceutical players to co-develop and commercialize its promising candidates, allowing it to share the risks and rewards inherent in drug development. These partnerships not only provide upfront payments and milestone-based financial inflows but also broaden the scope of clinical trials and expedite the pathway to market availability. By aligning their interests with larger entities invested in cutting-edge oncology solutions, Arcus is positioned to capitalize on the symbiotic relationship between innovative early-stage science and the expansive reach of established pharmaceutical channels, striving to bring transformative therapies to the global market.
See Also
What is Arcus Biosciences Inc's Change in Working Capital?
Change in Working Capital
22m
USD
Based on the financial report for Dec 31, 2024, Arcus Biosciences Inc's Change in Working Capital amounts to 22m USD.
What is Arcus Biosciences Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
194%
You don't have any saved screeners yet